University of California, Los Angeles

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).

897 total trials 158 currently recruiting 622 completed early-phase tilt top decile by trial count

University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.

University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

897 total, page 15 of 18

COMPLETED Phase 2

Trigeminal Nerve Stimulation for Depression: Dose Finding

NCT01343563

COMPLETED Phase 1

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970

COMPLETED Phase 4

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

NCT02123108

COMPLETED NA

Safety of Body Composition Analysis in Heart Failure Patients With Implantable Cardioverter Defibrillators (ICDs)

NCT01568606

COMPLETED Phase 3

Stroke Inpatient Rehabilitation Reinforcement of ACTivity

NCT01246882

COMPLETED Phase 1

Trigeminal Nerve Stimulation for Post Traumatic Stress Disorder (PTSD) and Depression

NCT01335217

COMPLETED Phase 2

Preventing Drug Use in Low Income Clinic Populations

NCT01942876

TERMINATED Phase 4

Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders

NCT01373918

COMPLETED Phase 4

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

NCT01225991

COMPLETED Phase 4

A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease

NCT01122329

COMPLETED NA

Vitamin D in HIV-Infected Patients on HAART

NCT01250899

COMPLETED Phase 2

Promotora-based Latino Family CVD Risk Reduction

NCT01714271

COMPLETED

Starting Treatment With Agonist Replacement Therapies Follow-up Study

NCT01592461

TERMINATED NA

Drum-Assisted Therapy for Native Americans

NCT01356667

COMPLETED NA

Effects of Vitamin D Insufficiency in Man

NCT01848236

TERMINATED NA

Wear Characteristics of Denture Teeth

NCT01188226

COMPLETED Phase 1

Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis

NCT01219647

TERMINATED Phase 1

Pain, Opioids and Pro-Inflammatory Immune Responses

NCT01210066

COMPLETED NA

Exhaled Carbon Monoxide (eCO) for Diffusing Capacity (DLCO) Correction

NCT01126047

COMPLETED Phase 2

HIV and Fat Accumulation

NCT01088295

COMPLETED NA

Endothelin Blockade in Patients With Single Ventricle Physiology

NCT00989911

COMPLETED Phase 1

A Study to Compare the Effects of Different Sized Particles on Cells in the Nose

NCT01257191

COMPLETED Phase 4

Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

NCT01185977

COMPLETED Phase 1

Remote Ischemic Preconditioning in Subarachnoid Hemorrhage

NCT01158508

COMPLETED NA

Mindfulness Based Relapse Prevention for Stimulant Users

NCT01094223

COMPLETED NA

Evaluating an Emergency Department Observation Syncope Protocol for Older Adults

NCT01003262

COMPLETED NA

Meditation to Reduce Caregiver Stress

NCT01537679

COMPLETED NA

Exercise to Improve Outcomes of Treatment for Methamphetamine Users

NCT01103531

COMPLETED Phase 2

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234

COMPLETED NA

UCLA-Amity Parolee Health Promotion Study

NCT01844414

COMPLETED NA

Iyengar Yoga for Young People With Irritable Bowel Syndrome

NCT01107977

COMPLETED NA

UCLA Tai Chi in a Community Setting Study

NCT01203657

COMPLETED NA

Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis

NCT01907282

COMPLETED Early Phase 1

Curcumin in Rheumatoid Arthritis

NCT00752154

COMPLETED NA

Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to "Stay Within the Guidelines"

NCT00861081

TERMINATED Phase 1

Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease

NCT01046773

COMPLETED NA

Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents

NCT01118988

COMPLETED NA

Interventions for Communication in Autism Network

NCT01018407

COMPLETED Phase 2

Benefits of Walnuts for Male Reproductive Health

NCT01505140

COMPLETED Phase 2

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

NCT01011829

COMPLETED Phase 4

Biomarkers for Outcomes In Late-life Depression (BOLD)

NCT01082237

COMPLETED NA

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

NCT00999037

COMPLETED Phase 2

Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents

NCT00994448

TERMINATED Phase 1

Safety Assessment of Atomoxetine With MA IV Administration

NCT01019707

TERMINATED Phase 4

Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques

NCT00992108

COMPLETED NA

Management of Diabetes With Metformin In Patients With Chronic Heart Failure

NCT01122316

COMPLETED Phase 1

Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)

NCT00352599

COMPLETED NA

Healthy Lifestyle Behavior Intervention for Latino Women

NCT01333241

TERMINATED Phase 2

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

NCT00969332

COMPLETED NA

Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose

NCT00882115

← Previous Page 15 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 112
Phase 2 82
Phase 3 22
Phase 4 76

What is open in the University of California, Los Angeles pipeline

158 recruiting of 897 indexed (18% open); 622 completed (69%).

Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Los Angeles: open-pipeline peers nationwide

Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20% Total trials Recruiting share University of California, Los AngelesIndiana UniversityHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders Network
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 897 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, Los Angeles page

897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.

  • 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.